BR112017017112A2 - composição farmacêutica, uso de composição farmacêutica na preparação de medicamento, e método de tratamento de hipoparatireoidismo - Google Patents

composição farmacêutica, uso de composição farmacêutica na preparação de medicamento, e método de tratamento de hipoparatireoidismo

Info

Publication number
BR112017017112A2
BR112017017112A2 BR112017017112A BR112017017112A BR112017017112A2 BR 112017017112 A2 BR112017017112 A2 BR 112017017112A2 BR 112017017112 A BR112017017112 A BR 112017017112A BR 112017017112 A BR112017017112 A BR 112017017112A BR 112017017112 A2 BR112017017112 A2 BR 112017017112A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition
hypoparathyroidism
drug preparation
treating hypoparathyroidism
Prior art date
Application number
BR112017017112A
Other languages
English (en)
Other versions
BR112017017112B1 (pt
Inventor
Rothner Ariel
Burshtein Gregory
GALITZER Hillel
M Schwartz Phillip
Original Assignee
Entera Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd filed Critical Entera Bio Ltd
Publication of BR112017017112A2 publication Critical patent/BR112017017112A2/pt
Publication of BR112017017112B1 publication Critical patent/BR112017017112B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição farmacêutica, uso de composição farmacêutica na preparação de medicamento, e método de tratamento de hipoparatireoidismo, descreve neste documento uma composição farmacêutica para uso no tratamento de hipoparatireoidismo por administração oral da composição; a composição compreende paratormônio ou um fragmento respectivo e snac (8-n-(2-hidroxibenzoil) aminocaprilato de sódio). são divulgados também os usos da composição na preparação de um medicamento e métodos de tratamento de hipoparatireoidismo utilizando a composição.
BR112017017112-0A 2015-02-09 2016-02-09 Composição farmacêutica BR112017017112B1 (pt)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562113604P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
US201562113600P 2015-02-09 2015-02-09
US201562113638P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113619P 2015-02-09 2015-02-09
US201562113629P 2015-02-09 2015-02-09
US62/113,673 2015-02-09
US62/113,619 2015-02-09
US62/113,638 2015-02-09
US62/113,629 2015-02-09
US62/113,625 2015-02-09
PCT/IL2016/050151 WO2016128970A1 (en) 2015-02-09 2016-02-09 Treatment of hypoparathyroidism

Publications (2)

Publication Number Publication Date
BR112017017112A2 true BR112017017112A2 (pt) 2018-04-03
BR112017017112B1 BR112017017112B1 (pt) 2023-08-15

Family

ID=

Also Published As

Publication number Publication date
US20180036382A1 (en) 2018-02-08
CA3011654A1 (en) 2016-08-18
IL253802A0 (en) 2017-09-28
US20240181020A1 (en) 2024-06-06
CN114949185A (zh) 2022-08-30
IL303216A (en) 2023-07-01
IL253803A0 (en) 2017-09-28
IL253802B (en) 2022-06-01
IL253804A0 (en) 2017-09-28
EP3256153A1 (en) 2017-12-20
JP2023100920A (ja) 2023-07-19
IL253803B (en) 2021-06-30
EP3256152A1 (en) 2017-12-20
EP3256153A4 (en) 2018-11-21
CN107427481A (zh) 2017-12-01
US20180028622A1 (en) 2018-02-01
EP3256113A4 (en) 2018-11-14
CN113713090A (zh) 2021-11-30
IL253804B (en) 2022-05-01
CA3011657A1 (en) 2016-08-18
CN113730556A (zh) 2021-12-03
IL292218B1 (en) 2024-06-01
MX2017010220A (es) 2018-02-21
CN113694190A (zh) 2021-11-26
JP2018504444A (ja) 2018-02-15
HK1247823A1 (zh) 2018-10-05
HK1247822A1 (zh) 2018-10-05
IL292417A (en) 2022-06-01
JP2023055902A (ja) 2023-04-18
JP6925969B2 (ja) 2021-08-25
IL283258B1 (en) 2023-07-01
US20180050096A1 (en) 2018-02-22
JP2018504445A (ja) 2018-02-15
CN113713090B (zh) 2023-06-02
IL283258B2 (en) 2023-11-01
JP6925970B2 (ja) 2021-08-25
CA2975710C (en) 2023-08-08
JP7275207B2 (ja) 2023-05-17
HK1247838A1 (zh) 2018-10-05
CA2975676A1 (en) 2016-08-18
WO2016128974A1 (en) 2016-08-18
JP2021176914A (ja) 2021-11-11
US20180036234A1 (en) 2018-02-08
CA2975710A1 (en) 2016-08-18
JP2021176913A (ja) 2021-11-11
WO2016128973A1 (en) 2016-08-18
HK1247843A1 (zh) 2018-10-05
WO2016128971A1 (en) 2016-08-18
EP3256152A4 (en) 2018-11-14
WO2016128970A1 (en) 2016-08-18
US10583177B2 (en) 2020-03-10
EP3256149A1 (en) 2017-12-20
US20180021272A1 (en) 2018-01-25
IL292218A (en) 2022-06-01
MX2022014313A (es) 2022-12-07
EP3256149A4 (en) 2019-08-14
EP3256114A1 (en) 2017-12-20
EP3256113A1 (en) 2017-12-20
EP3256114A4 (en) 2018-11-21
WO2016128972A1 (en) 2016-08-18
HK1247835A1 (zh) 2018-10-05
IL283258A (en) 2021-07-29
CA2975578A1 (en) 2016-08-18
CN113694190B (zh) 2024-05-07
US20200138913A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
UY37271A (es) Composiciones nasales de cannabinoides
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112015018168A2 (pt) inibidores de rock suaves
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
BR112018077541A2 (pt) formulações orais gastrorretentivas e usos das mesmas
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011064-1 PROTOCOLO 870230048130 EM 05/06/2023 18:02.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2016, OBSERVADAS AS CONDICOES LEGAIS